<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is usually around the age of 70 </plain></SENT>
<SENT sid="1" pm="."><plain>Despite this, most clinical trials are restricted to younger subjects </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, the management of elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is not always optimal </plain></SENT>
<SENT sid="3" pm="."><plain>Physiologically, elderly patients show characteristics that differ from those of younger patients and that condition their pharmacological treatment </plain></SENT>
<SENT sid="4" pm="."><plain>In this regard, the comprehensive geriatric assessment (CGA) becomes particularly important </plain></SENT>
<SENT sid="5" pm="."><plain>This document gathers conclusions from the 1(st) Meeting of Members of the Sociedad Española de Medicina Geriátrica and the Sociedad Española de Hematología y Hemoterapia, with the objective of proposing the establishment of CGA instruments to assist in the decision-making process of elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The results of this consensus document will focus on the diagnosis, prognosis, treatment and management of adverse events in this age group </plain></SENT>
</text></document>